BPC July 08 update

Stocks rally on analyst coverage: Aerpio ARPO +63%; 9 Meters NMTR +20%; ATAI +11%

Price and Volume Movers

Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) shares closed up 63% to $2.79. Analysts at HC Wainwright & Co. upgraded their rating of the stock to Buy from Neutral with a price target of $22.00.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) shares also rallied on the back of analyst coverage. BMO Capital initiated coverage of the company with an Outperform rating and a price target of $5.00. Shares closed up 20% to $1.24.

F-star Therapeutics, Inc. (NASDAQ: FSTX) announced a licensing agreement with AstraZeneca plc (NASDAQ: AZN) where AstraZeneca will receive access to F-star’s novel preclinical Stimulator of Interferon Genes (STING) inhibitors. SVB Leerink also initiated coverage of the stock with an Outperform rating and a price target of $39.00. Shares closed up 9% to $8.01.

Atai Life Sciences N.V. (NASDAQ:ATAI) shares closed up 11% to $19.48. Aegis Capital initiated coverage with a Buy rating and a price target of $26.00.

Vor Biopharma (Nasdaq: VOR) announced a collaboration with Janssen Biotech, Inc. (Johnson & Johnson) to develop its engineered hematopoietic stem cell (eHSC) therapies with Janssen's bi-specific antibodies for acute myeloid leukemia (AML). Financial terms were not disclosed. Shares of Vor closed up 9% to $19.79.

-

Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Alterity Therapeutics Limited (ATHE): $2.02; +28%.

Ambrx Biopharma Inc. (AMAM): $21.84; +11%.

Cassava Sciences, Inc. (SAVA): $106.00; +10%.

CohBar, Inc. (CWBR): $1.38; +10%.

Protagenic Therapeutics, Inc. (PTIX): $2.61; +9%.

DECLINERS:

Virpax Pharmaceuticals, Inc. (VRPX): $4.54; -12%.

Evaxion Biotech A/S (EVAX): $6.13; -10%.

BriaCell Therapeutics Corp. (BCTX): $4.76; -8%.

Kiromic BioPharma, Inc. (KRBP): $4.30; -7%.

ARCA biopharma, Inc. (ABIO): 3.48; -7%.

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

AMGN – Amgen Inc.
Tezepelumab
Asthma

$241.54
-0.92  -0%
PDUFA priority review PDUFA date under priority review estimated around January 8, 2022.
$138.8 billion

EVAX – Evaxion Biotech A/S
EVX-01 and KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab)
Melanoma/NSCLC/Bladder cancer

$5.40
-0.08  -1%
Phase 1/2 Phase 1/2 data released July 8, 2021. Objective Response Rate (ORR) of 67%. 22% Complete Response (CR) and 44% Partial Response (PR).
$103.7 million

EVAX – Evaxion Biotech A/S
EVX-02
Adjuvant melanoma

$5.40
-0.08  -1%
Phase 1/2 Phase 2 trial to be initiated 2Q 2022.
$103.7 million

LIFE – aTyr Pharma Inc.
ATYR1923
Pulmonary sarcoidosis

$4.66
+0.08  +2%
Phase 1/2 Phase 1/2 data due September 2021.
$74.9 million

PSTI – Pluristem Therapeutics Inc.
PLX-PAD
COVID-19 / Acute Respiratory Distress Syndrome (ARDS)

$3.28
-0.06  -2%
Phase 2 Phase 2 data due 4Q 2021.
$104.1 million